Trademark Overview
On Thursday, October 31, 2024, a trademark application was filed for HERANOVA with the United States Patent and Trademark Office. The USPTO has given the HERANOVA trademark a serial number of 98831068. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, October 31, 2024. This trademark is owned by Heranova Lifesciences Inc.. The HERANOVA trademark is filed in the Pharmaceutical Products, Medical Instrument Products, and Medical & Beauty Services & Agricultural Services categories with the following description:
Medical diagnostic assay test and analysis for the presence of biomarkers in blood or bodily fluids for diagnosing gynecological diseases, namely endometriosis; Medical diagnostic assay test and analysis for the presence of biomarkers in uterine tissue for determining a patient's personalized and optimal embryo implantation time and for determining a patient's personalized treatment plan, as well as the composition of microbiome, including presence of normal lactobacillus and targeted pathogenic bacteria, namely, Escherichia, Klebsiella, Enterococcus, Streptococcus, Mycoplasma, Chlamydia, Ureaplasma, Neisseria, Staphylococcus, and Gardnerella; Medical diagnostic assay test and analysis for the presence of biomarkers in uterine and vaginal tissue for determining a patient's personalized treatment plan; for bacterial, fungal and resistance markers for determining a personalized treatment plan; Medical diagnostic assay test and analysis for the presence of biomarkers in human biological m...
Providing medical information in the field of gynecology; medical information services in the gynecological field; medical testing services for diagnostic purposes in the field of gynecology, namely, testing services for detecting endometritis, a woman's personalized embryo implantation time, and/or Pelvic Inflammatory Disease and antibiotic resistance either post-partum or in cases of unexplained infertility; medical diagnostic services for gynecological diseases and disorders, namely, for detecting endometriosis by identifying and analyzing biomarkers for diagnostic and/or treatment purposes; medical assessment services, namely, health assessment and predictive services for estimating remaining childbearing years based on patient-specific health information.
Medical devices, namely, surgical and nonsurgical devices for treating endometriosis, infertility, and gynecological diseases and disorders.